chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Booster; The Covid booster shot (probably in fat not muscle) left quite a dent in the fat mass on my arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (005570). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administered in arm (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "Booster"; VACCINATION SITE REACTION (medically significant), outcome "recovered", described as "The Covid booster shot (probably in fat not muscle) left quite a dent in the fat mass on my arm".  Additional information:  You might have something in the vaccine that can destroy fat cells. Maybe very very low diluted doses with size 26 needles? And months later it still seems to be working and the dent has smoothed out and my upper arm looks great!  The lot number for bnt162b2 was not provided and will be requested during follow up.
Vaccine on 04/10/21.Shortness of breath, dizziness, nausea 04/13/2021. Death on at hospital on 04/14/2021 Autopsy found Bilateral pulmonary thromboemnbolus
Initial unsolicited report received from a physician on 02-Feb-2017. This case involves a two-month-old male patient who was vaccinated with a first dose of DAPTACEL (batch number: C4780AA, expiry date, dose form and frequency not reported) intramuscularly in left thigh and first dose of ACT HIB (batch number UI415AAB, expiry date, dose form and frequency not reported) intramuscularly in the right thigh on 06-Jan-2017. Pre-existing physician diagnosed allergies, birth defects, medical conditions (specify) and Illness at time of vaccination was reported as none. It was reported that the patient received soy formula along with breast feeding. Concomitant medications were not reported. Any other vaccines with four weeks of vaccination were not reported. On 07-Jan-2017, 12 hours following the vaccination, the patient experienced diarrhea and generalized rash. The patient was evaluated in the emergency department. Relevant laboratory investigations were not reported. The patient received topical steroids as corrective treatment. On an unspecified date, the patient recovered from the events. List of documents held by the sender: None.
Information has been received from a registered nurse concerning an 18 weeks old patient, who on 09-JUL-2010 was vaccinated with a first 2 ml dose of ROTATEQ (Lot # not reported) PO. No adverse effect was reported. Additional information has been requested.
This spontaneous report as received from a Registered Nurse refers to unknown number of patients of unknown age and gender. Since 26-APR-2015, the patients were vaccinated with (Merck) PROQUAD (subcutaneous; dosage, lot # not provided) which had undergone supported temperature excursions. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Ears ringing, ears plugged, very dizzy (progressed during the day), fever, weakness, muscle aches and feverish feeling. Wheezing/shortness of breath. Dizziness worse when getting up or sitting down, sudden turn of head.
pt recvd vax 19APR93 & mom brought pt to clinic to have PPD reading taken & said pt was limping & on exam lt leg was swollen & warm;
Found apneic and unresponsive. CPR was run x 2h but patient never revived. Cause of death was determined to be SIDS. No other SIDS risk factors were present. Baby was asleep on back in proper bed without blankets or pillows.
Patient stated she felt lightheaded and scratchy throat after receiving flu immunization. Patient stated she has never received flu vaccine in the past.  Nurse checked vital signs, vital signs were stable. Patient continued to complain of feeling of itchy throat. Nurse  administered epinephrine 1 x and called 911. patient was transported via ambulance to hospital.  Patient remained awake, alert and oriented through entire event.
Pain at injection site; Tiredness; Headache; Chills; Joint pain; Fever; Felt paralyzed at one point; This is a spontaneous report from a contactable consumer.  A 60-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), lot number: K5730, via an unspecified route of administration from 29Dec2020 16:15 at a SINGLE DOSE for covid-19 immunization. Medical history included migraine with aura. Concomitant medication included gabapentin, pravastatin, estradiol, diphenhydramine hydrochloride (ALLERGY), and ascorbic acid, calcium pantothenate, colecalciferol, cyanocobalamin, nicotinamide, pyridoxine hydrochloride, retinol, riboflavin, thiamine hydrochloride, tocopherol (VITAM).  The patient previously took amoxicillin and had allergies.  On 30Dec2020 15:00, the patient experienced pain at injection site, tiredness, chills, joint pain, fever and felt paralyzed at one point. The outcome of events was recovering.  No follow-up attempts possible. No further information expected.
COVID-19 positive; COVID-19 positive; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from regulatory authority. The reporter is the patient.  An adult female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 15Jan2022 (Lot number: FL3209) as dose 3 (booster), single, intramuscular, administration date 13May2021 (Lot number: EW0185) as dose 2, single and intramuscular, administration date 22Apr2021 (Lot number: EW0170) as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset 23Jan2022, outcome "unknown", COVID-19 (medically significant) with onset 23Jan2022, outcome "recovering" and all described as "COVID-19 positive". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (23Jan2022) positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of covid-19.  Clinical Course: Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Hospitalization Prolonged: No, Prior to vaccination, patient was not diagnosed with COVID-19.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on the known safety profile and Limited information in the case report a casual association between the LOE events  with the suspect drug BNT162B2 cannot be excluded.
Site of vaccine has pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A 68-year-old female patient received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 immunization, reaction(s): "Site of vaccine has no pain, unlike previous 3 Pfizer"; Bnt162b2 (Dose 2), for COVID-19 immunization, reaction(s): "Site of vaccine has no pain, unlike previous 3 Pfizer". The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "Site of vaccine has pain".  Additional information: It was reported that the site of vaccine had no pain, unlike previous 3 Pfizer and one Moderna vaccine or booster. The patient had a reaction every single time before.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201182250 Similar report from same reporter (Pfizer bivalent booster);US-PFIZER INC-202201182345 Similar report from same reporter (1st dose);US-PFIZER INC-202201182346 Similar report from same reporter (2nd dose);
Jawhas pain on the right side; Has a headache; Arm is still sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN JAW (Jawhas pain on the right side), HEADACHE (Has a headache) and VACCINATION SITE PAIN (Arm is still sore) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 03-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN JAW (Jawhas pain on the right side), HEADACHE (Has a headache) and VACCINATION SITE PAIN (Arm is still sore). At the time of the report, PAIN IN JAW (Jawhas pain on the right side), HEADACHE (Has a headache) and VACCINATION SITE PAIN (Arm is still sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
2nd dose still not given; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 79-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2019).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix as per the vaccination schedule, which led to incomplete course of vaccination. The reporter consented to follow up.
temp to 100, 2-3 hrs post vax followed by fatigue;felt warm x 2-3 days;then mild cold like sx-nasal stiffness & flu like feeling;
injection site pain 8 hours post injection. Fever 100.1 overnight with body aches and chills, headache; injection site pain 8 hours post injection. Fever 100.1 overnight with body aches and chills, headache; injection site pain 8 hours post injection. Fever 100.1 overnight with body aches and chills, headache; injection site pain 8 hours post injection. Fever 100.1 overnight with body aches and chills, headache; injection site pain 8 hours post injection. Fever 100.1 overnight with body aches and chills, headache; This is a spontaneous report from a contactable consumer. A 52-year-old female patient received the first dose of bnt162b2 (BNT162B2, lot number: EJ1685), via an unspecified route of administration in right arm on 17Dec2020 11:00 at a single dose for immunization, administered in the hospital. Medical history included allergies to Penicillin, crustaceans. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medication included herbal remedies: Guanyin Pearls, Shu Gan Tang. The patient experienced injection site pain 8 hours post injection, fever of 100.1 overnight with body aches, chills and headache on 17Dec2020 07:00. The outcome of the events was recovering. The events did not caused hospitalization. Since the vaccination, the patient has not been tested for COVID-19.
Pt experienced numbness legs & hands, sweating, H/A with standing, giddiness, backache that came & went & felt like may experience SOB lasted about 1 hour.
Pt presented for 2nd primary dose of Pfizer covid vaccine on 04/10/203; pt 5 years old. First primary dose received at 4 years old with Pfizer 6 months ? 4 years covid vaccine. Pt received Pfizer 5 years ? 11 years as second dose in primary series on 04/10/2023.  Pt waited 15 min after injection for observation. No signs or symptoms of adverse reaction noted.
Headaches Tiredness Palpation Shortness of breath Joint pain Dizziness Heart racing high blood pressure  high than it normally is
No adverse event to report. Submitting VAERS report due to patient being 15 years old at time of vaccination with Pfizer COVID-19 vaccine. 1st dose appointment was scheduled by the patient via the mobile app on 3/23/21. 2nd dose was inadvertently scheduled  on 3/30/21. I reached out to the patient's parent and she verified that pt's date of birth is correct in Epic, it is 1/16/2006. She is 15. I asked if she had consented to the daughter's vaccination and states she did authorize to receive the vaccine on 3/30/21. The patient has her 2nd dose scheduled on 4/22/21 and this appt will be cancelled. I have communicated the need to carefully screen patient age with onsite staff since current Colorado Vaccination phase is all people >16yo.
Pt received her second booster of Pfizer at 3:15pm on 4/12, she started experiencing  rash like symptoms and itching on her hands, arms and trunk area  around 9am on 4/13.  She took Claritin and used Cortisone but not much relief.
Tingling on right side of face, tongue swelling, difficulty swallowing, left neck pain, left eye blurred vision. Progression in about 15 minutes. 50mg BENADRYL taken immediately. Symptoms subsided within 40-45 minutes.
Hives on face, spread to ear, foot, cheeks were rock hard. After Benadryl it went down. Came back next day twice as bad in different locations. administered Benadryl.  Within an hour both arms were completely covered in a matter of 10 minutes.  After given drugs at hospital next day came back again while at doctors office, treated again, still has hives. Also has maintained a low grade fever throughout.
red rash all over her body; welts on both her ankles/itchy welt; ankles which were itchy; diagnosed with chicken pox; red / at the injection site; rash / at the injection site / radiated like a line all the way down to her left wrist; itching at the injection site; This case was reported by a consumer via call center representative and described the occurrence of chickenpox in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included chickenpox (chicken pox in first grade).   On 21st September 2020, the patient received the 1st dose of Shingrix (intramuscular). On 22nd September 2020, 1 days after receiving Shingrix, the patient experienced chickenpox, injection site erythema, injection site rash and injection site itching. On 24th September 2020, the patient experienced welts and localized itching. On 25th September 2020, the patient experienced red rash. The patient was treated with steroids nos (Steroids). On an unknown date, the outcome of the chickenpox, injection site erythema, injection site rash, injection site itching, welts, localized itching and red rash were unknown.   It was unknown if the reporter considered the chickenpox, injection site erythema, injection site rash, injection site itching, welts, localized itching and red rash to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix vaccine in her left deltoid intramuscularly and had red, rash and itching at the injection site which radiated like a line all the way down to her left wrist. The patient had welts on both her ankles which were itchy and red rash all over her body and went to the Emergency room, where she was diagnosed with chicken pox.  The patient was started on a 5 day course of steroid which completed. The itching had stopped but she continues to had the rash all over her body. The reporter consented to follow up.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history, concurrent conditions and concomitant medications was provided. On unknown dates, the patients were vaccinated with improperly stored doses of MMR II, lot# K024035, expiration date: 26-NOV-2016 and lot# K014832, expiration date: 14-SEP-2016, (dose, route of administration, albumin status and injection site were not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
patient always has syncope episodes after vaccination or blood drown. she warned pharmacist about possible syncope.  she was given cold/wet towel to put on her chest before vaccination and advised to drink cold water.patient was sitting during shot and pharmacist was talking to her before during an after  shot to disrupt her. around 2 minutes after shot , she tilted her head, closed her eyes and started to shake for about  20 seconds then opened her eyes and asked what had happened. she was pale and had cold sweats on her face. she started to drink cold water/ Gatorade , ate nuts and started to feel better. pulse was normal, blood pressure was   90/70. 10 minutes later patient was feeling fine and blood pressure is 110/80 at 11:05am. patient was feeling fine and left.
This spontaneous report was received from a medical assistant concerning an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not reported. On unspecified dates, the patients were vaccinated with improperly stored doses of PEDVAXHIB lot # reported as M024261, expiration date: 30-JUL-2018, as prophylaxis (Strength, dose and route of administration were not reported), which experienced a temperature excursion of 46.5 Fahrenheit degrees for 20 minutes. A previous excursion of 46.5 Fahrenheit degrees for 20 minutes was reported. Data logger was involved. No adverse effects were reported. This is one of several reports received from the same reporter. Lot # M024261 is an invalid lot # for PEDVAXHIB. Additional information has been requested. Sender's Comments: US-009507513-1612USA012399: US-009507513-1701USA001262: US-009507513-1701USA001264: US-009507513-1701USA001265: US-009507513-1701USA001266: US-009507513-1701USA001267.
indication: Treatment of COVID-19; indication: Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 44-year-old male patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). No known allergy. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "indication: Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (13Jul2022) Negative, notes: tested negative on 13Jul, 14Jul; (14Jul2022) Negative, notes: tested negative on 13Jul, 14Jul; (16Jul2022) Positive, notes: Scratchy throat on 16Jul, tested positive again. Therapeutic measures were taken as a result of drug ineffective, covid-19 including Paxlovid from 08Jul2022 to 12Jul2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Patient left pharmacy and passed out on the sidewalk.  Unknown if vaccine or fall caused Nausea, Headache, Memory loss.
headache started about 45 min after shot, laid down on couch (at home) and fell asleep (30 min +/-)  when awoke tongue felt a little thick, drank water then tongue felt sore on top and "hairy", but a lot less thick. headache subsiding.  tongue top still sore 4 hours later
No additional adverse effect reported; Nurse reported administered GARDASIL9 after temperature excursion; This spontaneous report as received from a nurse and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical histories provided.  On 23-JUL-2020, the patient was vaccinated with improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 milliliter (lot # reported as 16374 is an invalid lot number for hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), expiration date reported as 16-FEB-2022, route of administration was not provided). There was no adverse effect reported. The vaccine underwent a temperature excursion of 8 degrees Celsius (C) (8.83 C) for 20 hours. The digital data logger was involved. There were no previous temperature excursions reported.
Large 3"/2" patch of skin erythema, itchyness and hive like welts appeared about 9 days after the vaccine and spread rapidly on the arm. Treated with topicort cream once a day for 4 days. Itchyness has decreased slightly and some erythema and hives are still there on the patch.
Pt had fever up to 105, regressed in developmental areas, such as not pulling to stand or trying to walk.  Pt had electrodermal screening and was put on several homeopathic drops and is now walking.
The pain varies in location over my heart and chest.; chest pain; This is a spontaneous report from a contactable consumer (patient). A 22-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 24May2021 15:00 (Batch/Lot Number: EW0183) as dose 2, single for covid-19 immunisation at a hospital. Medical history included known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received other medications within 2 weeks of vaccination. The patient had the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EW1075) on 28Apr2021 15:30 in the left arm for Covid-19 immunization. The patient began having chest pain 3-4 days after his 2nd covid vaccine and this has continued since then. The pain occurs sometimes when resting but at all times when getting up and moving around.  For example, he has chest pain when he walks down the stairs and even when he was standing up and washing the dishes. The pain sometimes lasts for 5 minutes but at other times it lasts for hours. The pain varies in location over his heart and chest. No SOB. He had to take an LOA from his job because of the continued chest pain which would last for hours while he was at work. The events started on 28May2021 and resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The events were not treated. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was not recovered.
Pt vaccinated with TD/MMR c/o nausea, vomiting, chest pain, no audible B/P initially, dizziness, to emergency room B/P 112/78.
HOURS LATER I HAD FATIGUE JOINT SORENESS. HAD TROUBLE BREATHING. I WAS REALLY TIRED.
Headache, body aches, about a day; nausea and diarrhea, about a day
Headache, fatigue and fever of 101.8, Motrin and rest given.
Information has been received from a registered nurse (RN) concerning an elementary aged child who was vaccinated with a dose of Varivax. The RN reported hat in February 2006, the patient developed breakthrough chickenpox which was considered to be a light, mild case. Unspecified medical attention was sought. At the time of this report, the outcome was unknown. Additional information has been requested.
A couple of hours after the injection, my entire upper left arm began to swell, turn red and hot, and become painful. I was also nauseous and had a headache. By evening, I was unable to lift my arm higher than my chest. Eventually all parts of the upper arm from the level of the injection site to just below the elbow became severely swollen, hot, red, and painful. I applied ice. heat, arnica twice per day, and took aspirin twice per day. By 48 hours the swelling, pain, and redness began to diminish but some swelling and pain remains after 72 hours. At this point the some of the affected areas have a yellow/greenish tint.